Department of Surgery, Emory Transplant Center, Emory University, Atlanta, GA, USA.
Am J Transplant. 2013 Jul;13(7):1769-81. doi: 10.1111/ajt.12299. Epub 2013 Jun 3.
Preemptive kidney transplantation is the optimal treatment for pediatric end stage renal disease patients to avoid increased morbidity and mortality associated with dialysis. It is unknown how race/ethnicity and poverty influence preemptive transplant access in pediatric. We examined the incidence of living donor or deceased donor preemptive transplantation among all black, white, and Hispanic children (<18 years) in the United States Renal Data System from 2000 to 2009. Adjusted risk ratios for preemptive transplant were calculated using multivariable-adjusted models and examined across health insurance and neighborhood poverty levels. Among 8,053 patients, 1117 (13.9%) received a preemptive transplant (66.9% from LD, 33.1% from DD). In multivariable analyses, there were significant racial/ethnic disparities in access to LD preemptive transplant where blacks were 66% (RR = 0.34; 95% CI: 0.28-0.43) and Hispanics 52% (RR = 0.48; 95% CI: 0.35-0.67) less likely to receive a LD preemptive transplant versus whites. Blacks were 22% less likely to receive a DD preemptive transplant versus whites (RR = 0.78, 95% CI: 0.57-1.05), although results were not statistically significant. Future efforts to promote equity in preemptive transplant should address the critical issues of improving access to pre-ESRD nephrology care and overcoming barriers in living donation, including obstacles partially driven by poverty.
抢先进行肾移植是治疗儿科终末期肾病患者的最佳方法,可以避免因透析而导致的发病率和死亡率增加。种族/民族和贫困如何影响儿科患者的抢先移植机会尚不清楚。我们检查了 2000 年至 2009 年期间美国肾脏数据系统中所有黑人、白人和西班牙裔儿童(<18 岁)接受活体供体或已故供体抢先移植的发生率。使用多变量调整模型计算抢先移植的调整风险比,并根据医疗保险和社区贫困水平进行检查。在 8053 名患者中,有 1117 名(13.9%)接受了抢先移植(66.9%来自 LD,33.1%来自 DD)。在多变量分析中,黑人接受 LD 抢先移植的机会存在显著的种族/民族差异,黑人的可能性比白人低 66%(RR=0.34;95%CI:0.28-0.43),西班牙裔的可能性比白人低 52%(RR=0.48;95%CI:0.35-0.67)。与白人相比,黑人接受 DD 抢先移植的可能性低 22%(RR=0.78,95%CI:0.57-1.05),尽管结果没有统计学意义。未来在抢先移植方面促进公平的努力应该解决改善接受 ESRD 肾病学治疗的机会和克服活体捐赠障碍的关键问题,包括部分由贫困驱动的障碍。